Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Neuro-oncology advances（2021）
摘要
Baseline diffusion MRI and tumor volume are independent imaging biomarkers of OS in rGBM treated with BV or BV+VB-111.
更多查看译文
关键词
VB-111,anti-VEGF therapy,bevacizumab,diffusion MRI,imaging biomarker,recurrent GBM
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要